There was a lot of excitement when Tepezza became the first drug approved for the treatment of thyroid eye disease in January ...

Lyme disease is a complex condition with a long history of misdiagnosis, and Lyme arthritis, a late manifestation of the ...

New research indicates that medications commonly prescribed for weight reduction might offer significant benefits for asthma ...

Creatine supplementation may improve cognitive performance and mood, offering insights into its role in muscle-brain ...

Coya Therapeutics, Inc. (NASDAQ: COYA) ("Coya" or the "Company"), a clinical-stage biotechnology company focused on developing biologics that enhance regulatory T cell (Treg) function in patients with ...

Cytokine networks demonstrate dual functionality. Cytokines are key regulators of immune homeostasis, but paradoxically, cytokines also function as pathogenic drivers in diseases such as systemic ...

Giant cell arteritis (GCA) is the most frequent primary systemic vasculitis in adults, involving medium-to-large-sized ...

Topics covered include rising food allergies in children, the psychological burden of chronic allergic diseases, predictors ...

Obefazimod’s strong Phase 3 induction data positions Abivax as leading UC contender with novel mechanism and favorable safety ...

Current approaches in bioengineering are synthesized and methods for their implementation are suggested for the induction and modulation of trained immunity in the treatment of human diseases.

Detailed price information for Oncolytics Biotech Inc (ONCY-Q) from The Globe and Mail including charting and trades.